Valuation: BioNTech SE

Market Cap 24.38B 28.42B 22.76B 20.88B 39.27B 2,716B 39.92B 269B 105B 1,362B 107B 104B 4,504B P/E 2026 *
-17.6x
P/E 2027 * -18.7x
Enterprise Value 13.01B 15.16B 12.15B 11.14B 20.95B 1,449B 21.3B 143B 56.12B 727B 56.93B 55.7B 2,403B EV / Sales 2026 *
7.2x
EV / Sales 2027 * 7.78x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+21.96%
1 week+21.98%
Current month+24.88%
1 month+23.66%
3 months+28.85%
6 months+2.45%
Current year+18.82%
1 week 90.52
Extreme 90.52
116
1 month 88.2
Extreme 88.2
116
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
388
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+21.96%+21.98%+1.54%+2.50% 28.42B
-1.90%+3.12%+81.70%+110.88% 72.21B
-0.52%+15.75%+55.04%+91.45% 63.98B
+1.71%-1.22%+2.71%+501.29% 28.53B
+3.63%+8.57%+62.12%+24.72% 25.07B
+0.37%+6.72%+40.01%-13.39% 20.04B
0.00%-2.78%+247.46%+423.83% 18.19B
+1.81%+1.43%+23.67%+527.06% 15.96B
+2.39%+7.96%+44.96%+157.77% 13.48B
+1.72%+2.48%+350.20%+216.38% 12.63B
Average +3.12%+5.40%+90.94%+204.25% 29.85B
Weighted average by Cap. +2.30%+6.52%+73.06%+166.04%

Financials

2026 *2027 *
Net sales 1.81B 2.11B 1.69B 1.55B 2.91B 201B 2.96B 19.91B 7.8B 101B 7.91B 7.74B 334B 1.84B 2.15B 1.72B 1.58B 2.97B 205B 3.02B 20.31B 7.95B 103B 8.07B 7.89B 341B
Net income -1.35B -1.57B -1.26B -1.16B -2.17B -150B -2.21B -14.86B -5.82B -75.35B -5.9B -5.77B -249B -1.31B -1.53B -1.23B -1.12B -2.12B -146B -2.15B -14.47B -5.67B -73.38B -5.75B -5.62B -243B
Net Debt -11.37B -13.25B -10.62B -9.74B -18.32B -1,267B -18.62B -125B -49.05B -635B -49.76B -48.68B -2,101B -10.03B -11.69B -9.37B -8.59B -16.16B -1,118B -16.43B -111B -43.28B -561B -43.91B -42.95B -1,853B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
19/08/26 USD 113.12 +21.96% 8,780,347
18/08/26 USD 92.75 +1.26% 921,586
17/08/26 USD 91.60 -1.60% 443,531
14/08/26 USD 93.09 +1.05% 650,531
13/08/26 USD 92.12 -0.67% 988,541
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
97.03EUR
Average target price
104.08EUR
Spread / Average Target
+7.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock